GlassScriptPhysician profile
Helen M Dsa
NPI 1346374618
$10,265.15
in general payments reported to CMS, 2019-2025
29 companies · $1,654 in 2025
The $1,654 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,456 · 2020: $487 · 2021: $1,254 · 2022: $2,111 · 2023: $1,856 · 2024: $1,447 · 2025: $1,654.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,666 · Education: $291.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,665.60 |
| Education | $290.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $1,690.51 | 2019-2025 | Tremfya, Simponi, Stelara |
| Abbvie INC. | $1,390.25 | 2019-2025 | Rinvoq, Skyrizi, Botox |
| Novartis Pharmaceuticals Corporation | $1,103.17 | 2019-2025 | |
| Sun Pharmaceutical Industries INC. | $689.26 | 2019-2025 | Ilumya |
| Pfizer INC. | $494.25 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $467.10 | 2019-2024 | Dupixent |
| Dermavant Sciences, INC. | $437.34 | 2023-2024 | Vtama |
| Amgen INC. | $435.83 | 2019-2025 | Otezla, Enbrel |
| Leo Pharma INC. | $421.53 | 2021-2025 | Anzupgo, Adbry |
| Galderma Laboratories, L.P. | $387.33 | 2019-2025 | Nemluvio, Aklief |
| E.R. Squibb & Sons, L.L.C. | $368.44 | 2022-2025 | Sotyktu |
| Journey Medical Corporation | $365.98 | 2022-2025 | |
| Ucb, INC. | $354.62 | 2019-2025 | Bimzelx |
| Genzyme Corporation | $334.33 | 2019-2025 | |
| Incyte Corporation | $215.53 | 2022-2024 | Opzelura |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $185.05 | 2019-2025 | Taltz, Olumiant, Ebglyss |
| Celgene Corporation | $150.56 | 2019 | |
| Arcutis Biotherapeutics, INC. | $141.22 | 2023-2025 | Zoryve |
| Dermira, INC. | $140.53 | 2019 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $102.12 | 2019-2023 | Targretin |
| Sanofi-Aventis U.S. LLC | $96.99 | 2025 | |
| Janssen Scientific Affairs, LLC | $96.21 | 2021 | |
| Stemline Therapeutics INC. | $57.11 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $39.48 | 2022 | |
| Genentech USA, INC. | $31.07 | 2020-2021 | |
| Botanix Sb INC | $20.29 | 2025 | Sofdra |
| Almirall LLC | $17.76 | 2019 | |
| Verrica Pharmaceuticals INC. | $16.21 | 2023 | Ycanth |
| Cipher Pharmaceuticals US LLC | $15.08 | 2025 | Natroba, Spinosad |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Helen Dsa listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.